🇺🇸 FDA

Intelligence · Clinical Pipeline

Phase III Pipeline Programs

Late-stage pivotal and registrational clinical programs nearing regulatory submission.

Programs
5,427

Quick answer

NovaPharmaNews tracks 5,427 phase iii pharmaceutical pipeline programs from ClinicalTrials.gov. Late-stage pivotal and registrational clinical programs nearing regulatory submission.

Top sponsors

Page 85 of 114

  1. Secukinumab

    Novartis Pharmaceuticals

    Plaque Psoriasis

    phase 3 small molecule completed

    1 trial

  2. Secukinumab (75 mg)

    Novartis Pharmaceuticals

    Psoriatic Arthritis

    phase 3 small molecule completed

    1 trial

  3. Secukinumab 150 mg provided in 1.0 mL pre-filled syringes (PFSs) for sc injection.

    Novartis Pharmaceuticals

    Ankylosing Spondylitis

    phase 3 small molecule completed

    1 trial

  4. Selatogrel

    Viatris Pharmaceuticals Co.,

    Acute Myocardial Infarction

    phase 3 other active

    1 trial

  5. Selatogrel solution matching placebo, Selatogrel solution

    Viatris Pharmaceuticals Co.,

    Acute myocardial infarction (AMI)

    phase 3 small molecule active

    1 trial

  6. Selinexor

    Karyopharm Therapeutics Inc

    Dedifferentiated Liposarcoma

    phase 3 small molecule completed

    1 trial

  7. Selinexor

    Karyopharm Therapeutics Inc

    Endometrial Cancer

    phase 3 small molecule active

    2 trials

  8. Selinexor

    Karyopharm Therapeutics Inc

    Multiple Myeloma

    phase 3 small molecule active

    12 trials

  9. Selinexor (combination therapy)

    Karyopharm Therapeutics Inc

    Relapsed/Refractory Diffuse Large B-cell Lymphoma

    phase 3 small molecule active

    1 trial

  10. Selpercatinib

    Eli Lilly and Company

    Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  11. Semaglutide

    Novo Nordisk A/S

    Overweight

    phase 3 small molecule completed

    1 trial

  12. Semaglutide B 1.34 mg/mL PDS290 3.0 mL, Wegovy 2.4 mg solution for injection in pre-filled pen, Pre-filled syringe (glass) in a pre-filled pen: Semaglutide placebo Ia DV3396 pen-injector, 0.5 mL Semaglutide placebo Ib DV3396 pen-injector, 0.75 mL, Semaglutide B 0.68 mg/mL PDS290 1.5 mL, Semaglutide D 1.0 mg/mL DV3396, Semaglutide D 2.0 mg/mL DV3396, Wegovy 0.25 mg solution for injection in pre-filled pen, Wegovy 2.4 mg FlexTouch solution for injection in pre-filled pen, Semaglutide B 3.2 mg/mL PDS290 3.0 mL

    NovoThirteen

    Non-alcoholic steatohepatitis (NASH)

    phase 3 small molecule active

    1 trial

  13. Semuloparin sodium

    Sanofi Pasteur

    Venous Thromboembolism

    phase 3 small molecule terminated

    1 trial

  14. Sephience 250 mg oral powder in sachet, Sephience 1 000 mg oral powder in sachet

    PTC THERAPEUTICS, INC.

    Phenylketonuria

    phase 3 small molecule active

    1 trial

  15. Sepiapterin

    PTC THERAPEUTICS, INC.

    Phenylketonuria

    phase 3 small molecule active

    1 trial

  16. Seroquel Sustained Release (SR)

    AstraZeneca

    Schizophrenic Disorder

    phase 3 small molecule completed

    1 trial

  17. SerpinPC

    Centessa Pharmaceuticals plc

    Hemophilia a

    phase 3 small molecule completed

    3 trials

  18. Setmelanotide

    Rhythm Pharmaceuticals Netherlands B.V.

    Bardet Biedl Syndrome (BBS)

    phase 3 small molecule completed

    1 trial

  19. Setmelanotide

    Rhythm Pharmaceuticals Netherlands B.V.

    Hypothalamic Obesity

    phase 3 small molecule active

    3 trials

  20. Setmelanotide

    Rhythm Pharmaceuticals Netherlands B.V.

    Obesity

    phase 3 small molecule active

    1 trial

  21. Setmelanotide

    Rhythm Pharmaceuticals Netherlands B.V.

    Obesity Associated With Defects in Leptin-melanocortin Pathway

    phase 3 small molecule active

    2 trials

  22. Setmelanotide

    Rhythm Pharmaceuticals Netherlands B.V.

    Pro-opiomelanocortin (POMC) Deficiency Obesity

    phase 3 small molecule completed

    1 trial

  23. Setmelanotide

    Rhythm Pharmaceuticals Netherlands B.V.

    Leptin Receptor Deficiency Obesity

    phase 3 small molecule completed

    1 trial

  24. Setmelanotide

    Rhythm Pharmaceuticals Netherlands B.V.

    Bardet-Biedl Syndrome

    phase 3 small molecule completed

    1 trial

  25. Setmelanotide 2 mg

    Rhythm Pharmaceuticals Netherlands B.V.

    Bardet-Biedl Syndrome

    phase 3 small molecule completed

    1 trial

  26. Setrusumab

    Mereo BioPharma Group plc

    Osteogenesis Imperfecta

    phase 3 mab active

    2 trials

  27. Sevabertinib

    Bayer HealthCare AG

    Advanced Non-small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  28. Sevoflurane

    Universal Integrated

    Anesthesia

    phase 3 small molecule completed

    1 trial

  29. Sevoflurano Baxter 100% líquido para inhalación del vapor EFG, Propofol Fresenius 20 mg/ml emulsión inyectable y para perfusión EFG

    The George Institute

    Acute ischemic stroke

    phase 3 small molecule active

    1 trial

  30. Shingrix powder and suspension for suspension for injection Herpes zoster vaccine (recombinant, adjuvanted), Cladribine Placebo, cladribine

    Merck Sharp and Dohme

    Generalized Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  31. Sibeprenlimab 400 mg

    Otsuka Beijing Research Institute

    Immunoglobulin A Nephropathy

    phase 3 small molecule active

    1 trial

  32. Sibeprenlimab 400 mg s.c. Q4weeks

    Otsuka Beijing Research Institute

    Immunoglobulin A Nephropathy

    phase 3 small molecule active

    1 trial

  33. Sigvotatug Vedotin

    Pfizer

    Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  34. Sildenafil placebo, Remidia, 20 mg, tabletki powlekane

    Cardiol Therapeutics

    Patients with functionally single ventricle (FSV - functionally single ventricle) after Fontan operation. The term "functionally single ventricle" refers to congenital heart defects in which one of the ventricles is not fully developed and/or one of the valves is atresia/hypoplastic as a result, it is not possible to correct the intracardiac defect. Then, there are indications for the Fontan operation, i.e. a palliative procedure - total cavo-pulmonary connection (TCPC). In patients with a functionally single ventricle, more than one operation is necessary to separate the systemic and pulmonary circulation. As a result of these procedures, Fontan circulation is created, which consists in bypassing the right heart chambers and directing the venous blood to the pulmonary artery. This leads to the removal of the right-to-left shunt and improvement of arterial blood saturation and reduction of volume overload of the systemic ventricle. At the same time, there is an increase in systemic venous pressure and a decrease in cardiac output. Low pulmonary resistance in these patients is crucial for maintaining optimal hemodynamic conditions both at rest and especially during exercise. Even a slight increase in pulmonary resistance leads to reduced pulmonary blood flow, reduced initial depression of a single ventricle, and consequently to reduced cardiac output and worsened exercise tolerance. Thus, pulmonary resistance in these patients should be not only normal, but also as low as possible to ensure adequate single ventricular filling and adequate cardiac output. There is evidence that patients with Fontan surgery increase pulmonary resistance over time. The increase in pulmonary resistance in these patients may result from several factors, and above all from the progressive dysfunction of a single systemic ventricle and the lack of a subpulmonary chamber ensuring pulsatile pulmonary flow. Although the Fontan operation in many patients with an univentricular heart is a very good method of palliative treatment, which undoubtedly extends the survival of children born with this heart defect, it also inevitably leads to severe complications developing over the years. Patients after the Fontan operation are also characterized by a significant reduction in exercise capacity, which is observed both in clinical practice in reference centres dealing with patients with congenital heart defects, and in multi-centre studies. Among other things, it was shown that children after the Fontan operation obtained 30% lower values of peak oxygen uptake in the ergospirometric test compared to the control group of healthy children (Amadero P et al., Heart 2018). The reduced exercise capacity of patients and the development of Fontan circulatory complications affect both the quality of life and the prognosis of adult patients with univentricular heart.

    phase 3 small molecule active

    1 trial

  35. Simponi 50 mg solution for injection in pre-filled syringe., Simponi 45 mg/0.45 mL solution for injection in pre-filled pen., Simponi 100 mg solution for injection in pre-filled syringe.

    Janssen-Cilag Pty Ltd

    Ulcerative Colitis

    phase 3 small molecule active

    1 trial

  36. Simvastatina NORMON 10 mg comprimidos recubiertos con película EFG, Atorvastatina NORMON 20 mg comprimidos recubiertos con película EFG, Simvastatina NORMON 40 mg comprimidos recubiertos con película EFG, Atorvastatina NORMON 40 mg comprimidos recubiertos con película EFG, Atorvastatina NORMON 10 mg comprimidos recubiertos con película EFG, Atorvastatina Normon 60 mg comprimidos recubiertos con película, Simvastatina NORMON 20 mg comprimidos recubiertos con película EFG

    The George Institute

    Spontaneous lobar ICH

    phase 3 small molecule active

    1 trial

  37. Sinovac PCV13

    Sinovac Research and Development Co.,

    Pneumococcal Infectious Disease

    phase 3 mab active

    2 trials

  38. Sinovac PCV13

    Sinovac Research and Development Co.,

    Pneumococcal Infectious Diseases

    phase 3 mab active

    1 trial

  39. Sinovac rabies vaccine

    Sinovac Research and Development Co.,

    Rabies (Healthy Volunteers)

    phase 3 mab active

    2 trials

  40. Sipavibart, SODIUM CHLORIDE, EVUSHELD 150 mg + 150 mg solution for injection, EVUSHELD 150 mg + 150 mg solution for injection

    AstraZeneca AB

    COVID-19

    phase 3 small molecule active

    1 trial

  41. Sirolimus

    Ultragenyx UK Limited

    Lymphangioleiomyomatosis

    phase 3 small molecule completed

    1 trial

  42. Sirolimus

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Lupus Nephritis

    phase 3 small molecule active

    1 trial

  43. Sitaxsentan

    Pfizer

    Pulmonary Arterial Hypertension

    phase 3 small molecule terminated

    1 trial

  44. Skilarence 120 mg gastro-resistant tablets, MAGNESIUM STEARATE, MICROCRYSTALLINE CELLULOSE

    The George Institute

    Adrenomyeloneuropathy

    phase 3 small molecule active

    1 trial

  45. Sodio Cloruro Fresenius Kabi Italia 0,9%, solvente per uso parenterale, Samyr placebo (saline solution), SAMYR 400 mg/5ml polvere e solvente per soluzione iniettabile

    Mylan Pharma UK

    Major Depression Disorders

    phase 3 small molecule active

    1 trial

  46. Sodio ioduro (I131) Curium Netherlands 37-7400 MBq capsula rigida, TAPAZOLE 5 mg compresse

    Sana Biotechnology

    Graves' disease and Graves' orbitophaty

    phase 3 small molecule active

    1 trial

  47. Sodium Chloride 0.9% Intravenous Infusion, VRDN-001 (Insulin-like growth factor-1 receptor [IGF-1R] inhibitor)

    Viridian Pharma Ltd

    Thyroid eye disease

    phase 3 small molecule active

    1 trial

  48. Sodium Oxybate

    Jazz Pharmaceuticals Ireland Limited

    Binge Eating Disorder

    phase 3 small molecule completed

    1 trial

Frequently asked questions

How many Phase III pipeline programs are in the directory?

5,427 published programs match this development stage in our ClinicalTrials.gov index.

What defines this pipeline stage?

Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.